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Vascular endothelial growth factorTo evaluate the antiallergic effects of oral benzaldehyde in a murinemodel of allergic asthma and rhinitis, we di-
vided 20 female BALB/c mice aged 8–10 weeks into nonallergic (intraperitoneally sensitized and intranasally
challenged to normal saline), allergic (intraperitoneally sensitized and intranasally challenged to ovalbumin),
and 200- and 400-mg/kg benzaldehyde (allergic but treated) groups. The number of nose-scratching events in
10 min, levels of total and ovalbumin-speciﬁc IgE in serum, differential counts of inﬂammatory cells in broncho-
alveolar lavage (BAL) ﬂuid, titers of Th2 cytokines (IL-4, IL-5, IL-13) in BAL ﬂuid, histopathologic ﬁndings of lung
and nasal tissues, and expressions of proteins involved in apoptosis (Bcl-2, Bax, caspase-3), inﬂammation (COX-2),
antioxidation (extracellular SOD, HO-1), and hypoxia (HIF-1α, VEGF) in lung tissue were evaluated. The treated
mice had signiﬁcantly fewer nose-scratching events, less inﬂammatory cell inﬁltration in lung and nasal tissues,
and lower HIF-1α and VEGF expressions in lung tissue than the allergic group. The number of eosinophils and neu-
trophils and Th2 cytokine titers in BAL ﬂuid signiﬁcantly decreased after the treatment (P b 0.05). These results
imply that oral benzaldehyde exerts antiallergic effects in murine allergic asthma and rhinitis, possibly through
inhibition of HIF-1α and VEGF.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Allergic asthma and rhinitis are caused by an IgE-mediated hyper-
sensitivity reaction [1]. They worsen life quality and increase the eco-
nomic burden [2]. The available medications, including antihistamines,
mast cell stabilizers, and inhaled or systemic corticosteroids, have tran-
sient effects. Therefore, there is growing interest in research and devel-
opment of more potent and long-acting therapeutic agents.
Benzaldehyde is an aromatic aldehyde commonly used in the cos-
metic industry as a ﬂavoring agent, fragrance, or denaturant [3]. In the
United States and Europe, it is also used as a food additive. Previous
research has suggested its effectiveness against some tumors [4], but
only few studies have investigated its potential as an antiallergic drug.
Moreover, Lacroix et al. have suggested that exposure to benzaldehyde-
containing air decreases ovalbumin-induced allergic airway inﬂamma-
tion in mice with allergic asthma [5]. However, the effects of oral benzal-
dehyde have not been investigated.n at the 25th Congress of the
posium of Infection & Allergy of
olaryngology, Head and Neck
-ro, Junggu, Incheon 400-711,
0 3580.
. This is an open access article underTo elucidate the antiallergic effects of oral benzaldehyde, we evalu-
ated the (i) number of nose-scratching events in 10 min, (ii) levels of
total and ovalbumin-speciﬁc IgE in serum, (iii) differential counts of
inﬂammatory cells in bronchoalveolar lavage (BAL) ﬂuid, (iv) titers of
some Th2 cytokines (IL-4, IL-5 and IL-13) in BAL ﬂuid, (v) histopathologic
ﬁndings of lung and nasal tissues, and (vi) expressions of several pro-
teins involved in apoptosis (Bcl-2, Bax, caspase-3), inﬂammation
(COX-2), antioxidation (extracellular SOD, HO-1), and hypoxia (Hif-1α,
VEGF) in lung tissue using amurinemodel of allergic asthma and rhinitis.
2. Materials and methods
2.1. Animals
Weused 20 female BALB/cmice (Orient Bio, Seongnam, Korea) aged
8–10 weeks and free from any murine-speciﬁc pathogens. They were
raised in a well-controlled environment with a 12-h light–dark cycle
and had unrestricted access to ovalbumin-free food and water. All
mice were handled according to a protocol approved by the Animal
Care and Use Committee of Inha University (INHA-140211-273).
2.2. Systemic sensitization and intranasal challenge
To induce allergic asthma and rhinitis, we adopted a published pro-
tocol with slight modiﬁcations [6–8]. Under pathogen-free conditions,
40-μg/kg ovalbumin (Sigma-Aldrich, St. Louis, MO) diluted in sterilethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Effect of oral benzaldehyde on murine nose-scratching behavior. The number of
nose-scratching events in 10 min after the last intranasal challenge was compared
among the nonallergic, allergic, and 200- and 400-mg/kg benzaldehyde groups. Data rep-
resent medians and ranges (n= ﬁvemice/group). ***P b 0.001 compared with the nonal-
lergic group (Kruskal–Wallis test and Mann–Whitney U-test).
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injected intraperitoneally on experimental days 1, 5, 14, and 21 for sys-
temic sensitization. Thereafter, daily intranasal instillation of ovalbumin
diluted in sterile saline (20 μL of 25-mg/mL ovalbumin per mouse) was
performed until experimental day 35 (14 challenges in total).
The mice were divided into four equal groups (n= 5 mice/group).
Negative control animals were exposed to normal saline (nonallergic
group), while positive control animals were exposed to ovalbumin
(allergic group). The remaining allergic animals received either 200-
or 400-mg/kg benzaldehyde (Premier Botanicals Ltd, Independence,
OR) by oral gavage feeding 30 min before the intranasal challenges.
2.3. Enumeration of nose-scratching events
Twenty-four hours after the last intranasal challenge, eachmousewas
intranasally exposed to ovalbumin. The number of nose-scratching
events in 10 min was immediately recorded by two blind, independent
observers.
2.4. Serum and BAL ﬂuid collection
We used an aortic puncture technique to collect serum. BAL ﬂuid
was collected by normal saline lavage (~4mL) through an intratracheal
tube [7]. The ﬂuid was ﬁltered through wet gauze and centrifuged at
150 g for 10 min. The resultant pellet was suspended immediately in
4-mL saline. We determined the total cell numbers in duplicate with a
hemocytometer. Then, a 100-μL aliquot was centrifuged (Cytospin 2
cytocentrifuge; Thermo Fisher Scientiﬁc, Pittsburgh, PA) and cell viabil-
ity and total cell count were evaluated using the trypan blue exclusion
test. Using centrifuged preparations stained with Diff-Quik (Baxter
Scientiﬁc, Miami, FL), we determined differential cell counts in 500
cells per animal at 1000× magniﬁcation.
2.5. Enzyme-linked immunosorbent assay (ELISA)
We evaluated the levels of total and ovalbumin-speciﬁc IgE in serum
by ELISA as described previously [9]. Total IgE was measured and com-
pared with a known concentration of mouse IgE standard (BD Biosci-
ences, San Diego, CA). We used the optical density at 450 nm instead
of calculating the concentration with a standard solution. The titers
of IL-4, IL-5, and IL-13 were measured using individual ELISA kits
(BioSource International, Camarillo, CA) according to themanufacturer's
instructions.
2.6. Histopathology
After ﬁxation in a 10% formalin solution for 3 weeks, lung and nasal
tissues were embedded in parafﬁn according to standard methods, and
4-μm-thick sections were stained with hematoxylin and eosin to detect
cellular inﬁltration. The number of inﬁltrated cells around a single bron-
chiole and in 1 mm2 of the lamina propria of the nasal mucosa was
counted in 10 random high-power (400×) ﬁelds.
2.7. Western blot analysis
Lung tissue (left whole lung) from each animal was homogenized in
lysis buffer using a Teﬂon homogenizer. We removed cellular debris of
the homogenates by centrifuging at 1000 g for 10 min. Total protein
contents were determined using a bicinchoninic acid protein assay kit
(Thermo Fisher Scientiﬁc, Rockford, IL). SDS-polyacrylamide gel electro-
phoresiswas used for separating aliquots of protein extracts (20–60 μg).
We transferred them electrophoretically onto polyvinylidene diﬂuoride
membranes in a transfer buffer containing 25-mM Tris–HCl, 192-mM
glycine, and 10% methanol. The membranes were blocked with 5%
bovine serum albumin in Tris-buffered saline with 0.1% Tween-20 and
incubated with speciﬁc primary antibodies. They were then incubatedwith horseradish peroxidase-conjugated secondary antibodies. Immu-
noreactive bands were visualized by enhanced chemiluminescence
(Pierce) and analyzed using Bio-1D software (SIM International Group,
Newark, DE).
2.8. Statistical analysis
All statistical analyses were conducted with SPSS version 19.0 soft-
ware (IBM, Armonk, NY). We used the Kruskal–Wallis test and Mann–
Whitney U-test for intergroup comparisons. P b 0.05 was considered
signiﬁcant.
3. Results
3.1. Nose-scratching events and serum IgE levels
In comparisonwith the nonallergic group, the allergic group showed
a signiﬁcantly increased number of nose-scratching events in 10 min
after intranasal ovalbumin instillation. They also had signiﬁcantly
higher levels of total and ovalbumin-speciﬁc IgE in serum (P b 0.001).
The treated mice showed signiﬁcantly fewer nose-scratching events
than the allergic animals (P b 0.01, Fig. 1), but they had no signiﬁcant
decrease in serum IgE levels (P N 0.05; Fig. 2).
3.2. Inﬂammatory cell counts in BAL ﬂuid
The ovalbumin challenge signiﬁcantly increased the counts of inﬂam-
matory cells such as eosinophils, neutrophils, and lymphocytes in BAL
ﬂuid comparedwith the saline challenge (Pb 0.001). After benzaldehyde
treatment, a signiﬁcant decrease in the eosinophil and neutrophil counts
was observed (P b 0.05; Fig. 3). The number of lymphocytes also de-
creased, although no signiﬁcance difference was noted between the
treated and the allergic groups.
3.3. Th2 cytokine titers in BAL ﬂuid
The allergic group showed signiﬁcantly increased IL-4, IL-5, and
IL-13 levels in BAL ﬂuid when compared with the nonallergic group
Fig. 2. Effects of oral benzaldehyde on serum IgE levels. (a) Total and (b) ovalbumin-speciﬁc IgE levels in serumwere compared among the nonallergic, allergic, and 200- and 400-mg/kg
benzaldehyde groups. Data represent medians and ranges (n= ﬁve mice/group). ***P b 0.001 versus the nonallergic group (Kruskal–Wallis test and Mann–Whitney U-test).
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(no signiﬁcant difference compared with the nonallergic group). Nota-
bly, the 400-mg/kg benzaldehyde group showed signiﬁcantly lower
IL-4 levels in BAL ﬂuid than the 200-mg/kg benzaldehyde group
(P = 0.008; Fig. 4).
3.4. Histopathologic ﬁndings of lung and nasal tissues
The allergic animals showed signiﬁcantly more inﬂammatory cell
inﬁltration around bronchioles and in the lamina propria of the nasal
mucosa than the nonallergic group. After benzaldehyde treatment, the
degree of cellular inﬁltration signiﬁcantly decreased (Fig. 5). The num-
ber of inﬁltrated eosinophils around a single bronchiole and in 1 mm2
of the lamina propria of the nasal mucosa also signiﬁcantly decreased
after the treatment (P b 0.05; Fig. 6).
3.5. Expressions of proteins related to various pathways
The allergic group showed increased expressions of Bcl-2, Bax, and
caspase-3. Although the treated groups showed no signiﬁcant differ-
ences in Bcl-2 and Bax expressions compared with the allergic group,
caspase-3 expression signiﬁcantly decreased in the 400-mg/kg benzal-
dehyde group (Fig. 7a).
Further, the allergic mice showed increased expressions of COX-2
and HO-1 and decreased expression of extracellular SOD comparedFig. 3. Effects of oral benzaldehyde on number of inﬂammatory cells in BAL ﬂuid. (a) Eosinoph
allergic, allergic, and 200- and 400-mg/kg benzaldehyde groups. Data represent medians and ra
Wallis test and Mann–Whitney U-test).with the nonallergic mice. After the treatment, signiﬁcant suppression
of COX-2 and HO-1 expressions was noted, but extracellular SOD ex-
pression was not signiﬁcantly recovered compared with the allergic
group (Fig. 7b).
The allergic group showed increased HIF-1α and VEGF expressions
compared with the nonallergic group; the expressions were signiﬁcantly
suppressed by the benzaldehyde treatment (Fig. 7c).4. Discussion
2In our study, benzaldehyde-treated allergic mice showed signiﬁ-
cantly fewer nose-scratching episodes than untreated allergic mice. To
the best of our knowledge, this is the ﬁrst study reporting the antiallergic
effects of oral benzaldehyde in murine allergic asthma and rhinitis. Pa-
tients with allergic rhinitis suffer from impaired life quality due to aller-
gic symptoms such as runnynose and sneezing. Therefore, benzaldehyde
treatment could signiﬁcantly improve life quality of such patients.
In several studies of the antiallergic effects of therapeutic antibodies,
we found that protocols in which treatment was started in the ovalbu-
min injection period led to decreased serum IgE levels [6], but the levels
did not signiﬁcantly decrease when treatment was started after sensiti-
zation [10]. In the present study, we started the treatment after com-
plete sensitization to ovalbumin, so oral benzaldehyde should have
had minimal or no effect on the serum titers of IgE. The signiﬁcant
post-treatment reduction in serum IgE levels despite systemicil, (b) neutrophil, and (c) lymphocyte counts in BAL ﬂuid were compared among the non-
nges (n= ﬁvemice/group). *P b 0.05, ***P b 0.001 versus the nonallergic group (Kruskal–
Fig. 4. Effects of oral benzaldehyde on Th2 cytokine titers in BAL ﬂuid. (a) IL-4, (b) IL-5, and (c) IL-13 titers in BAL ﬂuid were compared among the nonallergic, allergic, and 200-
and 400-mg/kg benzaldehyde groups. Data represent medians and ranges (n= ﬁve mice/group). **P b 0.01, ***P b 0.001 versus the nonallergic group (Kruskal–Wallis test and
Mann–Whitney U-test).
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fects through mechanisms independent of mast cell degranulation
and IgE. This result is clinically meaningful because patients with al-
lergic asthma and rhinitis are systemically sensitized to provocative
allergens.
Benzaldehyde treatment signiﬁcantly reduced the counts of eo-
sinophils, neutrophils, and lymphocytes in BAL ﬂuid. Similarly,
Lacroix et al. suggested that inhaled benzaldehyde decreases eosino-
phil and neutrophil counts in BAL ﬂuid [5]. As eosinophils, neutro-
phils, and lymphocytes play a pivotal role in the initiation and
maintenance of allergic inﬂammation, a decrease in the cell counts
implies a beneﬁcial antiallergic effect.
Th2 cytokines contribute to initiation andmaintenance of allergic re-
sponses [11], and are involved in airway eosinophilia and hyper-
responsiveness [12]. More speciﬁcally, IL-4 expression is related to
differentiation of Th2 lymphocytes, synthesis of IgE, upregulation of
IgE receptors, and hypersecretion of mucus [13–15]. IL-5 plays a role
in eosinophilic inﬂammation and its inﬁltration of the airway [16]. IL-13
is related to differentiation of B lymphocytes and isotype switching of
antibody to IgE [17]. Oral benzaldehyde signiﬁcantly reduced Th2 cyto-
kine titers in BAL ﬂuid, suggesting that it may exert its antiallergic effect
by blocking Th2 cytokine activity. The histopathologic ﬁndings support
these results.Fig. 5.Histopathologicﬁndings of lung andnasal tissues. (a–d) Lung and (e–h) nasal tissue sectio
with hematoxylin and eosin and compared under 400× magniﬁcation.We found the upregulation of several proteins associated with apo-
ptosis in the allergicmice, which is in agreementwith previousﬁndings.
Bcl-2 is upregulated in BAL ﬂuid of patients with severe asthma [18] and
nasal mucosa of patients with allergic rhinitis [19]. In a rat model of
experimentally induced allergic rhinitis, Suo et al. found that Bcl-2 and
Bax are signiﬁcantly upregulated in glandular cells, epithelial cells, and
eosinophils [20]. After challenge with house dust mite extracts,
caspase-3 is upregulated in human bronchiolar and nasal epithelial
cells [21]. However, benzaldehyde treatment didn't cause a signiﬁcant
change in the overall expression of these proteins in this study. There-
fore, we speculate that the antiallergic effects of benzaldehyde are inde-
pendent of the antiapoptotic pathway.
COX-2 expression was signiﬁcantly increased in the allergic mice
but signiﬁcantly decreased after the benzaldehyde treatment. Inhibition
of COX-2 exerts an antiallergic effect through the downregulation of
prostaglandin D2 [22]. The expression of extracellular SOD signiﬁcantly
declined in the allergic mice. There are few studies on the role of
extracellular SOD in allergic airway inﬂammation. In epithelial mucosa
of patients with eosinophilic sinusitis, SOD activity is signiﬁcantly sup-
pressed [23]. Extracellular SOD inhibits maturation of dendritic cells,
controls activation and proliferation of T lymphocytes, and regulates
differentiation of Th2 and Th17 cells [24]. Therefore, extracellular SOD
appears to ameliorate ovalbumin-induced allergic airway inﬂammationns of the nonallergic, allergic, and 200- and 400-mg/kg benzaldehyde groupswere stained
Fig. 6.Effects of oral benzaldehyde on inﬂammatory cell inﬁltration in lung and nasal tissues. The number of inﬁltrated cells (a) around a single bronchiole and (b) in 1mm2 of the
lamina propria of the nasal mucosa was compared among the nonallergic, allergic, and 200- and 400-mg/kg benzaldehyde groups. Data represent medians and ranges (n= ﬁve
mice/group). *P b 0.05, **P b 0.01 versus the nonallergic group (Kruskal–Wallis test and Mann–Whitney U-test).
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extracellular SOD and antioxidative mechanisms.
HO-1, a speciﬁc regulator of endogenous carbon monoxide, has a
protective effect in allergic airway inﬂammation. It inhibitsmast cell de-
granulation and synthesis of several Th2 cytokines. HO-1 thus protects
against airway inﬂammation and hyper-responsiveness and hyper-
secretion of mucus [25]. In our study, HO-1 expression signiﬁcantly in-
creased after induction of allergic asthma and rhinitis, but was
signiﬁcantly suppressed after the benzaldehyde treatment. Interesting-
ly, suppression of HO-1 expression was concentration dependent.Fig. 7. Effects of oral benzaldehyde on expressions of proteins involved in apoptosis, inﬂamma
extracellular SOD, and HO-1; and (c) HIF-1α and VEGF in lung tissue were quantiﬁed by Wes
and 400-mg/kg benzaldehyde groups. A: nonallergic group, B: allergic group, C: 200 mg/kg
mice/group). *P b 0.05, **P b 0.01 versus the nonallergic group; #P b 0.05, ##P b 0.01 versus thAccording to Yu et al., ovalbumin-sensitized guinea pigs show high
expression of HO-1, which is suppressed after treatment with dexa-
methasone [26]. Elhini et al. also suggested that HO-1 is upregulated
in patients with persistent allergic rhinitis [27]. Therefore, HO-1 is a
potential therapeutic target for allergic airway inﬂammation [25,28,
29]. HO-1 suppression may contribute to the antiallergic effects of
benzaldehyde.
HIF is a heterodimer composed of 2 subunits (α and β). Expres-
sion of the β subunit is constitutive, for HIF expression is mainly reg-
ulated through its α subunit [30]. Under hypoxia, HIF upregulatestion, antioxidation, and hypoxia. Expressions of (a) Bcl-2, Bax, and caspase-3; (b) COX-2,
tern blot analysis and SDS–PAGE and compared among the nonallergic, allergic, and 200-
treatment group, D: 400 mg/kg treatment group. Data represent means ± SD (n = ﬁve
e allergic group.
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adhesion molecules, and VEGF. HIF-1α expression is signiﬁcantly in-
creased in mice with allergic airway inﬂammation and humans with al-
lergic asthma and rhinitis [30]. Agents that inhibit HIF-1α (e.g., 2-
methoxyestradiol and HIF-1 siRNA) lead to reduction in HIF-1α and
VEGF expression, allergic airway response [31,32], inﬂammatory cell in-
ﬁltration, airway hyper-responsiveness, and Th2 cytokine levels [32].
Therefore, the antiallergic effects of benzaldehyde could also be attribut-
ed to the suppression of HIF-1α and VEGF expressions.
According to a recent report on benzaldehyde toxicity, the oral
median lethal dose (LD50) of benzaldehyde is about 800–1600 mg/kg
in experimental rats and mice [3]. The dose without side effects (no
observed adverse effect level [NOAEL]) is 400 mg/kg in mice [3]. We
therefore selected 400 mg/kg as the maximal dose of oral benzalde-
hyde. In fact, no deaths or signiﬁcant adverse events were noted in the
treated groups. By additional study with a lower drug regimen, we
could determine the optimal dose for excellent antiallergic effects and
improved safety.
Benzaldehyde is categorized as a food additive in the United
States and also a ﬂavoring substance in European countries [3]. A
commercially available US perfume contains up to 0.5% of benzalde-
hyde [3]. It is also naturally present in ordinary foods such as alcohol-
ic beverages, dairy products, tea, coffee, cocoa, and fruit, whose
concentration ranges from 0.01 to 8.9 ppm [3]. In other words,
humans are exposed to low-dose benzaldehyde by subcutaneous or
oral routes. In several human clinical studies, systemic allergic reac-
tion, phototoxicity, photosensitization, and reproductive or develop-
mental toxicity to benzaldehyde were absent or rare [3]. In rats,
benzaldehyde demonstrated no carcinogenicity. On the contrary, it
showed carcinostatic or antitumor effects [3]. Further study to eval-
uate the safety and efﬁcacy of oral or intranasal benzaldehyde in
allergic asthma or rhinitis is required.
The 200- and 400-mg/kg benzaldehyde groups showed few differ-
ences in this study. To achieve the maximal antiallergic effects with
minimal side effects, a lower drug concentration is desirable. We are
now performing similar experiments with much lower concentrations
of oral benzaldehyde (20–50 mg/kg).
In conclusion, oral benzaldehyde exerts antiallergic effects inmurine
allergic asthma and rhinitis, possibly through inhibition of HIF-1α and
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